BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9815553)

  • 1. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors.
    Yoshimoto M; Caminada De Toledo SR; Monteiro Caran EM; de Seixas MT; de Martino Lee ML; de Campos Vieira Abib S; Vianna SM; Schettini ST; Anderson Duffles Andrade J
    Am J Pathol; 1999 Nov; 155(5):1439-43. PubMed ID: 10550298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
    Zhang H; He X; Miao Q; Li L; Song J; Jiang X
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttreatment complications in pediatric cervical neuroblastoma: A retrospective case series at a tertiary cancer center.
    Lopez J; Subramanian T; Durell J; Levyn H; Wong R; Shah J; LaQuaglia MP; Gerstle JT
    J Surg Oncol; 2024 Feb; 129(2):219-223. PubMed ID: 37850570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exportin-T: A Novel Prognostic Predictor and Potential Therapeutic Target for Neuroblastoma.
    Pan LJ; Chen JL; Wu ZX; Wu YM
    Technol Cancer Res Treat; 2021; 20():15330338211039132. PubMed ID: 34469238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage 4N neuroblastoma before and during the era of anti-G
    Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of MYCN Gene Amplification in Pediatric Neuroblastomas: Development of a Deep Learning-Based Tool for Automatic Tumor Segmentation and Comparative Analysis of Computed Tomography-Based Radiomics Features Harmonization.
    Yeow LY; Teh YX; Lu X; Srinivasa AC; Tan E; Tan TSE; Tang PH; Kn BP
    J Comput Assist Tomogr; 2023 Sep-Oct 01; 47(5):786-795. PubMed ID: 37707410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-based
    Suematsu M; Yagyu S; Hosoi H; Iehara T
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34972781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
    Vermeulen J; De Preter K; Naranjo A; Vercruysse L; Van Roy N; Hellemans J; Swerts K; Bravo S; Scaruffi P; Tonini GP; De Bernardi B; Noguera R; Piqueras M; Cañete A; Castel V; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Michon J; Combaret V; Fischer M; Oberthuer A; Ambros PF; Beiske K; Bénard J; Marques B; Rubie H; Kohler J; Pötschger U; Ladenstein R; Hogarty MD; McGrady P; London WB; Laureys G; Speleman F; Vandesompele J
    Lancet Oncol; 2009 Jul; 10(7):663-71. PubMed ID: 19515614
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Olivera GG; Yáñez Y; Gargallo P; Sendra L; Aliño SF; Segura V; Sanz MÁ; Cañete A; Castel V; Font De Mora J; Hervás D; Berlanga P; Herrero MJ
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between contrast-enhanced CT-measured extracellular volume fraction, histopathological features, and MYCN amplification status in abdominal neuroblastoma: a retrospective study.
    Wang H; Ding H; Xie M; Zhang L; Li T; Qin J; Chen X; He L
    Abdom Radiol (NY); 2023 Nov; 48(11):3441-3448. PubMed ID: 37452211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A finite mixture survival model to characterize risk groups of neuroblastoma.
    Hunsberger S; Albert PS; London WB
    Stat Med; 2009 Apr; 28(8):1301-14. PubMed ID: 19184977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma.
    Ruiz-Pérez MV; Sainero-Alcolado L; Oliynyk G; Matuschek I; Balboni N; Ubhayasekera SJKA; Snaebjornsson MT; Makowski K; Aaltonen K; Bexell D; Serra D; Nilsson R; Bergquist J; Schulze A; Arsenian-Henriksson M
    iScience; 2021 Feb; 24(2):102128. PubMed ID: 33659885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of MYCN-activating mutation and amplification in a patient with neuroblastoma.
    Kojima M; Touge R; Kurihara S; Saeki I; Takahashi S; Hiyama E
    Pediatr Blood Cancer; 2024 May; ():e31115. PubMed ID: 38773728
    [No Abstract]   [Full Text] [Related]  

  • 16. Chelators as Antineuroblastomas Agents.
    D'Acunto CW; Gbelcová H; Kaplánek R; Pospíšilová M; Havlík M; Ruml T
    Physiol Res; 2023 Oct; 72(S3):S277-S286. PubMed ID: 37888971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells.
    Li J; Peng J; Wu L; Shen X; Zhen X; Zhang Y; Ma H; Xu Y; Xiong Q; Zhu Q; Zhang P
    J Biol Chem; 2023 Jul; 299(7):104856. PubMed ID: 37230388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
    Bartolucci D; Montemurro L; Raieli S; Lampis S; Pession A; Hrelia P; Tonelli R
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN protein stability is a better prognostic indicator in neuroblastoma.
    Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
    BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic analysis of E2F transcription factors E2F1 and E2F3 in four independent pediatric neuroblastoma cohorts.
    Wang H; Wang X; Xu L; Zhang J
    BMC Pediatr; 2022 Jun; 22(1):376. PubMed ID: 35764946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.